Related Experiment Video
Updated: Jun 3, 2026
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
[Stereotactic body radiaton therapy for 15 patients with small lung neoplasms]
Rong Yu1, Yongheng Li, Guangying Zhu
1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiation Oncology, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China.
Background And Objective:
It has been known that stereotactic radiotherapy has been widely used in clinical practice. The aim of this study is to evaluate the feasibility to treat small lung neoplasms with hypofraction stereotactic radiotherapy.
Methods:
From September 2005 to November 2009, 15 patients with non-small cell lung cancer and solitary metastatic lung cancer were treated with hypofraction stereotactic radiotherapy. Dose volume histogram was used to evaluated treatment plans. Lesion diameter 1.5 cm-4.0 cm. Toxicity was evaluated with the NCI-CTCAE 3.0 version. A dose 48 Gy-50 Gy was given in 4-10 fractions.
Results:
The short-term results showed that the complete response (CR) rate, the partial response (PR) rate, the overall response (CR+PR) rate, the one-year local control rate, the one-year survival rate was 60%, 20%, 80%, 100% and 86.67% respectively. Two patients had radiation pneumonitis of 0 grade. Acute radiation pneumonitis of grade I occurred in 9 patients, 4 patients had radiation pneumonitis of grade II and no patient developed serious (grade III) radiation pneumonitis.
Conclusions:
The hypofraction stereotactic radiotherapy is safe for small lung neoplasms.
